Targets › ITGAL
2 programs from 2 companies in 4 trials: 3 Phase 1, 1 Phase 3; Oncology, Ophthalmology; next expected readout Nov 2038.
Integrin ITGAL/ITGB2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. Integrin ITGAL/ITGB2 is a receptor for F11R. Integrin ITGAL/ITGB2 is a receptor for the secreted form of ubiquitin-like protein ISG15; the interaction is mediated by ITGAL. Involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes…. (UniProt, P20701)
Open in Phaseline: the race on ITGAL, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Lunan Better Pharmaceutical | Lifitegrast Integrin alpha-L/beta-2 (LFA-1) antagonist | ITGAL, ITGB2 | Phase 3 | Dry Eye Disease (DED) | – |
| Seattle Children's Hospital | Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T ce CD171-targeting CAR-T cells with 4-1BB:zeta costimulation | ITGAL | Phase 1 | Neuroblastoma | Nov 2038 |
Neuroblastoma (3) Dry Eye Disease (DED) (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.